根据一份公开的SEC文件显示,生物制药公司Dianthus Therapeutics Inc. (DNTH) 正着手调整其核心药物Claseprubart临床试验的筛选标准。该公司计划在2026年第一季度,将这些修改方案正式提交给美国食品药品监督管理局进行审阅。
根据一份公开的SEC文件显示,生物制药公司Dianthus Therapeutics Inc. (DNTH) 正着手调整其核心药物Claseprubart临床试验的筛选标准。该公司计划在2026年第一季度,将这些修改方案正式提交给美国食品药品监督管理局进行审阅。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.